Last reviewed · How we verify
Bivalent Moderna
Bivalent Moderna is a bivalent mRNA vaccine that encodes antigens targeting two variants of SARS-CoV-2 to elicit adaptive immune responses.
Bivalent Moderna is a bivalent mRNA vaccine that encodes antigens targeting two variants of SARS-CoV-2 to elicit adaptive immune responses. Used for COVID-19 prevention in adults and children (booster vaccination).
At a glance
| Generic name | Bivalent Moderna |
|---|---|
| Also known as | mRNA-1273.214 +B.1.1.529 OMI, mRNA-1273.214 |
| Sponsor | Murdoch Childrens Research Institute |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein (Wuhan and Omicron variants) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses lipid nanoparticle-formulated mRNA to instruct cells to produce spike proteins from both the original Wuhan strain and the Omicron variant, triggering both humoral and cellular immune responses. This bivalent approach aims to provide broader protection against circulating SARS-CoV-2 variants compared to monovalent vaccines.
Approved indications
- COVID-19 prevention in adults and children (booster vaccination)
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- COVID-19 Booster Study in Healthy Adults in Australia (PHASE3)
- COVID Booster in Pregnancy and Lactation
- Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants (PHASE2)
- Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern (PHASE2, PHASE3)
- Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial (PHASE3)
- COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders (PHASE2)
- A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
- COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bivalent Moderna CI brief — competitive landscape report
- Bivalent Moderna updates RSS · CI watch RSS
- Murdoch Childrens Research Institute portfolio CI